The FDA has granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 antibody, for the treatment of celiac disease.

Celiac disease, traditionally considered an autoimmune disease largely localised in the gastrointestinal tract, is an ...

The findings of a new study lend support for type 1 diabetes autoantibody screening in people with other autoimmune ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a ...

The only available treatment for a patient with coeliac disease is a strict gluten-free diet, which is often not enough on ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast ...

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celia ...

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of ...

Celiac disease is a serious autoimmune disorder ... When gluten is consumed, the immune system produces inflammatory cells and antibodies that attack the intestinal lining. This ongoing ...

An IgA anti-transglutaminase 2 (TGA-IgA) antibody cut-off of approximately 6.1 times the upper limit of normal optimised celiac disease diagnosis in children and adolescents with type 1 diabetes ...

Celiac disease (CD) is an autoimmune genetic disorder ... It is identified with blood tests that detect specific antibodies, namely anti-tissue transglutaminase (tTG) IgA, with a confirmatory ...

Celiac disease is an autoimmune condition triggered ... Blood samples were taken at every visit, with transglutaminase antibodies (tTGA) measured annually from 24 months onward to identify CDA.